Grifols reported an EPS of $0.24, meeting market expectations, with a revenue of approximately$2.14 billion.The company holds a Zacks Rank of #2 (Buy), indicating potential to outperform the broader market.Grifols showcases strong financial metrics, including a P/E ratio of 18.58 and a debt-to-equity ratio of 1.71.Grifols (NASDAQ:GRFS) is a prominent player in the medical sector, known for its focus on producing plasma-derived medicines and other healthcare products. The company operates in a competitive l ...